DeCure for Brain compression

Decompressive craniectomy is the only intervention with repeated clinical support for life-threatening brain compression, but the evidence base is narrow and its limitations are explicit. A 2011 review notes that medical therapy can mitigate intracranial pressure rises but that surgery is reserved for when hypertension becomes life-threatening; a 2007 review of decompressive surgery for space-occupying hemispheric infarction states that most reports are retrospective with low patient numbers, that control groups in prospective trials had higher age and more co-morbidities, and that long-term outcome data are insufficient. Preliminary randomised trial data reported in 2006 were described as very positive, but the same review calls the treatment promising rather than proven. A 2018 report on 371 patients with traumatic brain compression describes differentiated operative indications and analysed outcomes for intracranial haematomas and depressed fractures, but gives no survival or functional numbers in the abstract.

Experimental work on the mechanism of compression injury points to a specific molecular pathway but has not reached clinical translation. A 2000 study using organotypic brain slice cultures subjected to dynamic mechanical stretch found differential regulation of 22 genes related to cell death and survival: 24 hours after stretch, BDNF, NGF and TrkA expression increased significantly, while bcl-2, CREB and GAD65 decreased (p < 0.05); CREB and GAD65 expression correlated negatively with strain, and APP695 negatively with strain rate. A 2021 study in primary cortical neurons and a rat traumatic intracranial hypertension model found that controlled decompression (CDC) for 2–3 hours in vitro and 20–30 minutes in vivo attenuated compressive injury, reduced neuronal necroptosis and neuroinflammation, and increased activity of the two-pore domain potassium channel TREK-1; the TREK-1 blockers spadin and SID1900 partially reversed these protective effects. Compression alone aggravated injury, and CDC had no effect on RIP1 activity while reducing RIP3 activation.

The historical record shows how little has changed in the core question. Papers from 1894 and 1895, undertaken at the suggestion of Professor Horsley, investigated the elasticity of the living brain and recovery after short periods of compression, motivated by the frequency of brain compression as a pathological condition. That question — what mechanical parameters determine reversible versus irreversible injury — remains unresolved. The 2000 study explicitly found that gene expression responses were sensitive to both magnitude and rate of mechanical stimulus, and that specific genes correlated with strain or strain rate, but no clinical trial has used such parameters to stratify patients.

What is missing is not another mechanism paper. The 2021 TREK-1 work is preclinical and used pharmacological blockers in rodents; no human data exist for spadin or SID1900. The 2007 review identifies the decisive gaps: prospective randomised trials with adequate control groups, long-term functional outcome measures, and age-stratified analysis. The 2011 review similarly notes that despite a century of decompressive surgery, the procedure remains a rescue manoeuvre rather than a targeted therapy. No drug has been shown in any human trial to modify the molecular response to brain compression, and no trial has tested whether controlled decompression protocols alter outcomes in patients. Funding for a properly powered randomised surgical trial with blinded outcome assessment, and for translational work linking the in vitro strain-rate findings to patient imaging or pressure monitoring, is the immediate need.